- Home
- BMRA
BMRA
Biomerica Inc.
as 12-18-2024 12:32pm EST
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 7.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.24 - $1.51 | Next Earning Date: | 01-14-2025 |
| Revenue: | $5,509,000 | Revenue Growth: | 1.74% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Biomerica Inc. News
BMRA Breaking Stock News: Dive into BMRA Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Sector Update: Health Care Stocks Climb Thursday Afternoon
MT Newswires
a month ago
Biomerica inFoods Technology Gets Three International Patents
GlobeNewswire
a month ago
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
GlobeNewswire
a month ago
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements
GlobeNewswire
2 months ago
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
GlobeNewswire
2 months ago
Biomerica Reports First Quarter Fiscal 2025 Financial Results
GlobeNewswire
3 months ago
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
Simply Wall St.
4 months ago
Biomerica Full Year 2024 Earnings: US$0.35 loss per share (vs US$0.50 loss in FY 2023)
Compare BMRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMRA Biomerica Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.